I agree with you 100% dmb2. My list of milestones was not intended to be all-inclusive , and it only focused on the NWBO share price valuation based on developing the DCVAX-L vaccine to treat both ndGBM and rGBM patients in the US, UK, Canada, Germany and the rest of the 27 other EU countries.
My estimated value of the NWBO share price of $48 per share, and a buyout value of $72 per share does not include the following milestones:
(1) Getting DCVax-L approved to treat ndGBM and rGBM in the rest of the world (ROW).
(2) Getting DCVax-L approved worldwide to treat all or most other operable solid tumor cancers.
(3) Getting DCVax Direct approved worldwide to treat all or most inoperable solid tumor cancers.
I will update my valuation analysis after NWBio achieves all or most of the 6 milestones I have already listed. That valuation will be significantly higher than $48 per share, and a buyout value of $72 per share.
Market Data 
Markets 
AI
